PreemptiveAI emerged from stealth to unveil a foundation model aimed at transforming health prediction and monitoring. The model uses advanced signal processing to interpret biomedical signals from smartphones and wearables, extending Photoplethysmography (PPG) capabilities to provide deeper physiological insights. The company positions its technology for early disease detection with applications across patient care, precision medicine, and drug development. Founders Jamien McCullum, Leon Gatys, and Matt Whitehill draw on experience from Apple’s AI health work and doctoral research in health sensors. Incubated at the Paul Allen AI Institute, PreemptiveAI has formed a strategic partnership with Duke University to improve predictions of hospital readmissions and rising health risks. The company is backed by an initial $6.4M in funding and is preparing for further commercial deployments in 2024.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024